Clinical trial
1-Year Follow up to the 1473-IMIQ Study
NCT00114023 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00114023 |
|---|---|
| Title | 1-Year Follow up to the 1473-IMIQ Study |
| Official title | A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Keratosis |
| Intervention type | Drug |
| Interventions | Imiquimod 5% cream |
| Enrollment | 84 |
| Start date | Jan 1, 2005 |
| First posted | Jun 14, 2005 |
| Last update posted | Feb 19, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: